Features of anti-ischemic efficacy of trimetazidine MR, assigned in combination with metoprolol in patients with angina

Cover Page

Cite item

Full Text

Abstract

We studied the influence of trimetazidine MR on exercise tolerance and carbohydrate metabolism in 28 patients with stable effort angina, treated with metoprolol. The addition of trimetazidine MR to ongoing therapy with metoprolol substantially enhanced the antianginal and anti-ischemic efficacy of treatment. The most significant improvement was observed when the monotherapy with metoprolol wasn’t effective. In this subgroup of patients the threshold exercise duration increased by 77,1±18,1 s (p<0,05), the angina frequency decreased by 5,0±2,3 attacks per week (p<0,001) in comparison with metoprolol. Trimetazidine MR didn’t change the fasting blood glucose and insulin level and the index of fasting insulin resistance HOMA2-IR.

About the authors

P. Yu Bardybakhin

State Research Center for Preventive Medicine, Ministry of Health of the Russian Federation

E. V Bochkareva

State Research Center for Preventive Medicine, Ministry of Health of the Russian Federation

I. V Kim

State Research Center for Preventive Medicine, Ministry of Health of the Russian Federation

References

  1. Easteaugh J.L., Calvert M.J., Freemantle N. Highlighting the need for better patient care in stable angina: results of the international Angina Treatment Patterns (ATP) Survey in 7074 patients. Family Practice 2005; 22: 43–50.
  2. Daly C.A., Clemens F, Sendon J.L.L., Tavazzi L. et al. The initial management of stable angina in Europe from Euro Heart Survey. A description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur Heat J 2005; 26: 1011–22.
  3. Guidelines on the management of stable angina pectoris: executive summary. Task Force on the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–81.
  4. Диагностика и лечение стабильной стенокардии. Российские рекомендации, 2-й пересмотр. Кардиоваск. терапия и профилактика. 2008; 7 (6): 3–40.
  5. Метелица В.И., Бочкарева Е.В., Кокурина Е.В. и др. Индивидуальный выбор антиангинальных препаратов с помощью парных ВЭМ-тестов у больных стенокардией. Терапевт. арх. 1992; 9: 35–9.
  6. Бутина Е.К., Кокурина Е.В., Дмитриева Н.А. и др. Сниженная чувствительность к антиишемическому эффекту пропранолола и возможность ее коррекции у больных стабильной стенокардией. Терапевт. арх. 2002; 34–9.
  7. Sharma V, Dhillon P, Wambolt R et al. Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin - diabetic rat. Am J Physiol Heart Circ Physiol 2008; 294: H1609–H1620.
  8. Moro C, Polak J, Klimcakova E et al. Atrial natriuretic peptide stimulates lipid mobilization during repeated bouts of endurance exercise. Am J Physiol Endicrinol Metab 2006; 290 (5): E864–9.
  9. Moro C, Pillard F, Glisezinski I. et al. Exercise - induced lipid mobilization in subcutaneuos adipose tissue is mainly related to natriuretic peptides in overweight men. Am J Physiol Endocrinol Metab 2008; 295 (2): E505–13.
  10. Sarafidis P.A., Bakris G.L. Antihypertensive treatment with beta - blockers and the spectrum of glycaemic control. Q J Med 2006; 99: 431–6.
  11. Szwed H. Clinical benefits of trimetazidine in patients with recurrent angina. Coron Artery Dis 2004; 15 (1): 17–2.
  12. Ribeiro L.W., Ribeiro J.P., Stein R. et al. Trimetazidine added to combined hemodynamic anitianginal therapy in patients with type 2 diabetes: a randomized crossover trial. Am Heart J 2007; 154 (1): 78.e1–7.
  13. Fragasso G, Piatti P.M., Monti L et al. Short - and long - term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyoparthy. Am Heart J 2003; 146 (5): Е18.
  14. Cai J.S., Peng Z.J. Effect of trimetazidine on insulin resistance in patients with coronary heart disease. Nan fang Yi Ke Da Xue Xue Bao 2006; 26 (2): 222–6.
  15. Wallace N.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487–95.
  16. Geloneze B, Vasques A.C.J., Stabe C.F.C. et al. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome – Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metab 2009; 53 (2): 281–7.
  17. Vardeny O, Zebrack J, Gilbert E.M. Effects of beta - blocker titration on glucose homeostasis in heart failure. J Pharm Technol 2009; 25 (2): 71–8.
  18. Kantor P.F., Lucien A, Kozak R, Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long - chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580–8.

Copyright (c) 2013 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies